$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000139047820000026 Filed on August 13, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.987M	$2.638M
YoY Change	-24.68%	-46.26%
% of Gross Profit
Research & Development	$2.280M	$1.381M
YoY Change	65.1%	-13.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$4.267M	$4.019M
YoY Change	6.17%	-38.18%
Operating Profit	-$4.267M
YoY Change
Interest Expense	$0.00	$20.00K
YoY Change	-100.0%	-116.67%
% of Operating Profit
Other Income/Expense, Net	-$160.0K	-$3.134M
YoY Change	-94.89%	-46.87%
Pretax Income	-$4.430M	-$3.130M
YoY Change	41.53%	-46.95%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$4.425M	-$3.134M
YoY Change	41.19%	-48.3%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.66
Diluted Earnings Per Share	-$0.66	-$4.815M
COMMON SHARES
Basic Shares Outstanding	6.718M shares	25.18M shares
Diluted Shares Outstanding	6.718M shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.300M	$12.80M
YoY Change	-74.22%	884.62%
Cash & Equivalents	$3.300M	$12.75M
Short-Term Investments
Other Short-Term Assets	$1.900M	$900.0K
YoY Change	111.11%	-90.53%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.229M	$13.64M
YoY Change	-61.67%	24.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.000M	$400.0K
YoY Change	150.0%
Goodwill	$1.914M	$1.914M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$700.0K	$600.0K
YoY Change	16.67%	-60.0%
Total Long-Term Assets	$9.285M	$11.39M
YoY Change	-18.5%	-45.87%
TOTAL ASSETS
Total Short-Term Assets	$5.229M	$13.64M
Total Long-Term Assets	$9.285M	$11.39M
Total Assets	$14.51M	$25.03M
YoY Change	-42.02%	-21.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.426M	$3.762M
YoY Change	-35.51%	-68.91%
Accrued Expenses	$1.809M	$1.276M
YoY Change	41.77%	-74.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.325M	$5.400M
YoY Change	-19.91%	-78.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.100M	$4.900M
YoY Change	24.49%	-37.97%
Total Long-Term Liabilities	$6.100M	$4.900M
YoY Change	24.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.325M	$5.400M
Total Long-Term Liabilities	$6.100M	$4.900M
Total Liabilities	$10.73M	$10.70M
YoY Change	0.33%	-68.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$109.7M	-$89.53M
YoY Change	22.53%	31.19%
Common Stock	$113.5M	$103.9M
YoY Change	9.28%	57.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.783M	$14.34M
YoY Change
Total Liabilities & Shareholders Equity	$14.51M	$25.03M
YoY Change	-42.02%	-21.7%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$4.425M	-$3.134M
YoY Change	41.19%	-48.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.380M	-$4.660M
YoY Change	-27.47%	-26.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-20.00K	14.83M
YoY Change	-100.13%	252.26%
NET CHANGE
Cash From Operating Activities	-3.380M	-4.660M
Cash From Investing Activities
Cash From Financing Activities	-20.00K	14.83M
Net Change In Cash	-3.400M	10.17M
YoY Change	-133.43%	-586.6%
FREE CASH FLOW
Cash From Operating Activities	-$3.380M	-$4.660M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
CY2019Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.02
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-33958
	dei	Entity File Number EntityFileNumber	001-33958
	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
	dei	Entity Registrant Name EntityRegistrantName	SELLAS Life Sciences Group, Inc.
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	City Area Code CityAreaCode	(917)
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8099512
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7 Times Square, Suite 2503,
	dei	Local Phone Number LocalPhoneNumber	438-4353
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	SLS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9461978	shares
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	536000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3340000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7277000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2020Q2	gale	Stock Subscription Receivable Current StockSubscriptionReceivableCurrent	0	USD
CY2019Q4	gale	Stock Subscription Receivable Current StockSubscriptionReceivableCurrent	308000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1789000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	557000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	5229000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	8242000	USD
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	984000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	217000	USD
CY2020Q2	gale	In Process Research Development InProcessResearchDevelopment	5700000	USD
CY2019Q4	gale	In Process Research Development InProcessResearchDevelopment	5700000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	1914000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	1914000	USD
CY2020Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	687000	USD
CY2020Q2	us-gaap	Assets Assets	14514000	USD
CY2019Q4	us-gaap	Assets Assets	16609000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2426000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3902000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1809000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1171000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	90000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	217000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4325000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5290000	USD
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	918000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q2	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	262000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	262000	USD
CY2020Q2	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	33000	USD
CY2019Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	52000	USD
CY2020Q2	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	5193000	USD
CY2019Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	4912000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	10731000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	10516000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6717900	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6717900	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5080100	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5080100	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	7000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2020Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	113491000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	107235000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109715000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101147000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	3783000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	6093000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14514000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16609000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2280000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1381000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4144000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3240000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1987000	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2638000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4187000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5138000	USD
CY2020Q2	us-gaap	Costs And Expenses CostsAndExpenses	4267000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	4019000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	8331000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	8378000	USD
CY2020Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	16000	USD
CY2019Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-962000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-19000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1157000	USD
CY2020Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-143000	USD
CY2019Q2	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-95000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-281000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-482000	USD
CY2020Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1000	USD
CY2019Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	25000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	32000	USD
CY2020Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-158000	USD
CY2019Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	885000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-237000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	707000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4425000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3134000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8568000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7671000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17061000	USD
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	100000	USD
CY2020Q2	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	0	USD
CY2019Q2	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	952000	USD
	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	78000	USD
	gale	Dividend Arising From Warrant Modifications DividendArisingFromWarrantModifications	1391000	USD
CY2020Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4425000	USD
CY2019Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4086000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8646000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9062000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-16.56
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6717900	shares
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	645965	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6546440	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	547212	shares
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8062000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	146000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-4425000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3783000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6093000	USD
	gale	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	5963000	USD
	gale	Stock Issued During Period Value Pre Funded Warrant StockIssuedDuringPeriodValuePreFundedWarrant	4000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8568000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3783000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2950000	USD
CY2019Q2	gale	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	13416000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1045000	USD
CY2019Q2	gale	Stock Issued During Period Value Pre Funded Warrant StockIssuedDuringPeriodValuePreFundedWarrant	5000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	126000	USD
CY2019Q2	gale	Dividend Modification Of Warrants DividendModificationOfWarrants	70000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3134000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3300000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14338000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5245000	USD
	gale	Stock Issued During Period Value Common Stockand Warrants StockIssuedDuringPeriodValueCommonStockandWarrants	13416000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3275000	USD
	gale	Stock Issued During Period Value Pre Funded Warrant StockIssuedDuringPeriodValuePreFundedWarrant	5000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	311000	USD
	gale	Dividend Modification Of Warrants DividendModificationOfWarrants	243000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7671000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14338000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-8568000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-7671000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	291000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	311000	USD
	gale	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	24000	USD
	gale	Change In Operating Lease Right Of Use Assets ChangeInOperatingLeaseRightOfUseAssets	0	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	19000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	1153000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-281000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-482000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1383000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	315000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1476000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-263000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	638000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1038000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10212000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9647000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5963000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13781000	USD
	gale	Proceeds From Stock Subscription Receivable ProceedsFromStockSubscriptionReceivable	308000	USD
	gale	Proceeds From Stock Subscription Receivable ProceedsFromStockSubscriptionReceivable	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3280000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6275000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3937000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7414000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7377000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5451000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3440000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12865000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	25000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	32000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	976000	USD
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	550000	USD
	gale	Increase Decrease In Fair Value Of Warrant Liability IncreaseDecreaseInFairValueOfWarrantLiability	0	USD
	gale	Increase Decrease In Fair Value Of Warrant Liability IncreaseDecreaseInFairValueOfWarrantLiability	243000	USD
	gale	Noncash Offering Expense NoncashOfferingExpense	0	USD
	gale	Noncash Offering Expense NoncashOfferingExpense	365000	USD
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	818900	shares
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-109700000	USD
CY2020Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4300000	USD
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	227800147	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4549208	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1498000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2882000	shares
CY2020Q2	us-gaap	Prepaid Insurance PrepaidInsurance	1015000	USD
CY2019Q4	us-gaap	Prepaid Insurance PrepaidInsurance	200000	USD
CY2020Q2	gale	Prepaid Research And Development PrepaidResearchAndDevelopment	535000	USD
CY2019Q4	gale	Prepaid Research And Development PrepaidResearchAndDevelopment	224000	USD
CY2020Q2	gale	Prepaid Professional Services PrepaidProfessionalServices	104000	USD
CY2019Q4	gale	Prepaid Professional Services PrepaidProfessionalServices	49000	USD
CY2020Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	135000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	84000	USD
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1789000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	557000	USD
CY2020Q2	gale	Contract Research Payable ContractResearchPayable	1043000	USD
CY2019Q4	gale	Contract Research Payable ContractResearchPayable	371000	USD
CY2020Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	487000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	606000	USD
CY2020Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	279000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	194000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1809000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1171000	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	USD
CY2020Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	107000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	302000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	311000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	321000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	330000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1371000	USD
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	363000	USD
	gale	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	200000	USD
	gale	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	200000	USD
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1008000	USD
CY2019Q2	gale	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	100000	USD
CY2020Q2	gale	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	100000	USD
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	524097	shares
CY2019	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2700000	USD
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	818900	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1120000	shares
CY2019	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	300000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	208000	shares
CY2020Q2	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	101000	shares
CY2020Q2	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	8000	shares
CY2020Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1607000	shares
CY2019	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	75000	shares
CY2020Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	300000	USD
CY2019Q4	gale	Stock Subscription Receivable Current StockSubscriptionReceivableCurrent	300000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	302000	shares
	gale	Class Of Warrant Or Right Number Of Warrants Issued ClassOfWarrantOrRightNumberOfWarrantsIssued	1268000	shares
	gale	Class Of Warrant Or Right Number Of Warrants Exercised ClassOfWarrantOrRightNumberOfWarrantsExercised	449000	shares
	gale	Classof Warrantor Right Canceled Or Expired ClassofWarrantorRightCanceledOrExpired	1000	shares
CY2020Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1120000	shares
CY2019Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	52000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	0	USD
	gale	Fair Value Of Warrants Canceled FairValueOfWarrantsCanceled	0	USD
	gale	Fair Value Of Warrants Exercise Price Adjustment FairValueOfWarrantsExercisePriceAdjustment	0	USD
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	19000	USD
CY2020Q2	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	33000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	146000	USD
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	126000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	291000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	311000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0053
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0062
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0249
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0808
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0624
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9657
CY2020Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2019Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y2M12D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.35
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.53
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.00
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1000000.0	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y3M3D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	21520	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	112.81
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y11M23D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	186000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.87
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue	0	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	207520	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.38
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M29D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	197000	USD
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9681	shares
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	130.81
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M28D
CY2020Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
CY2020Q2	gale	Closing Price Of Common Stock ClosingPriceOfCommonStock	2.93

Files In Submission

Name	View Source	Status
0001390478-20-000026-index-headers.html	Edgar Link	pending
0001390478-20-000026-index.html	Edgar Link	pending
0001390478-20-000026.txt	Edgar Link	pending
0001390478-20-000026-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20200630.htm	Edgar Link	pending
gale-20200630.xsd	Edgar Link	pending
gale-20200630_cal.xml	Edgar Link	unprocessable
gale-20200630_def.xml	Edgar Link	unprocessable
gale-20200630_g1.jpg	Edgar Link	pending
gale-20200630_htm.xml	Edgar Link	completed
gale-20200630_lab.xml	Edgar Link	unprocessable
gale-20200630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sls20200630ex311nextgen.htm	Edgar Link	pending
sls20200630ex312nextgen.htm	Edgar Link	pending
sls20200630ex321nextgen.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2020 Q2 Form 10-Q Financial Statement

#000139047820000026 Filed on August 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2020 Q2 Form 10-Q Financial Statement

#000139047820000026 Filed on August 13, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls